Servier Completes Acquisition of Symphogen to Strengthen Antibody Capabilities in Oncology and Beyond

PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, announced that it has completed the acquisition of Symphogen A/S. In various therapeutic areas, including oncology, Symphogen will serve as Servier's Center of Excellence for antibodies. As a subsidiary of the Servier Group, Symphogen will maintain operational autonomy, continue to retain its experienced employees, and keep its headquarters in Ballerup, Denmark.

As part of this acquisition, Christophe Thurieau, Executive Director of the Servier Research Institute, has been appointed as CEO of Symphogen, while Symphogen’s former Chief Operating Officer, Karin Garre, has been appointed as General Manager of Symphogen. Martin Olin, Symphogen’s former CEO, will serve as an external advisor to support this transition.

Claude Bertrand, Executive Vice President in charge of Research and Development at Servier, stated: “The completion of this acquisition enables the Servier Group to strengthen its antibody capabilities in oncology and other therapeutic areas. The highly efficient Symphogen antibody discovery and research platform will enhance our R&D capabilities and pipeline strength, aligning with our goal of making life-saving treatments accessible to more patients worldwide.”

Christophe Thurieau, Executive Director of Les Laboratoires Servier and CEO of Symphogen, added, “In alignment with the values upheld by Symphogen, we firmly believe that innovation and collaboration are key to developing treatments that benefit patients. We are pleased to welcome Symphogen as part of the Servier Group and look forward to further collaboration with the team to develop breakthrough antibody therapies for patients.”

Karin Garre, General Manager of Symphogen, summarized: “The completion of this transaction marks the beginning of an exciting journey for Symphogen and Servier. Built upon the foundation of our previous strategic collaboration and leveraging Symphogen’s robust capabilities, this acquisition will support Servier’s R&D strategy in the antibody field. Given the strong alignment between the core values of both companies, I believe this acquisition will yield even greater achievements in the future.”

PDF：https://mma.prnewswire.com/media/1175338/Servier_PDF_EN.pdf
Icon:https://mma.prnewswire.com/media/1175327/Servier_Logo.jpg